B-Phage

B-Phage is a biotech startup dedicated to tackling the antimicrobial resistance (AMR) crisis by isolating bacteriophages and harnessing AI-driven technology to ultimately develop innovative therapeutics.

Bacteriophage therapy is a viable alternative to traditional antibiotics, for treating both drug-resistant and drug-susceptible infections.

The market opportunity for phage therapy is closely tied to the growth of the antibiotic market, driven by the urgent need for alternative treatments amid rising antibiotic resistance.

B-Phage is actively developing a comprehensive biorepository of bacteriophages and their host bacteria; with the next phase of development focusing on clinical trials to evaluate the most promising phage candidates.

To facilitate the development and application of bacteriophage therapy, B-Phage is also developing AlphaPhage – an AI-powered computational platform that is designed to predict phage-host interactions.

B-Phage's competitive advantage lies in conducting research and development in South Africa, leveraging the region’s unique microbial diversity, cost-effective operations, and emerging market opportunities to drive innovation in bacteriophage therapeutics.